Repare Therapeutics Inc. (RPTX) News

Repare Therapeutics Inc. (RPTX): $24.46

1.70 (+7.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RPTX News Items

RPTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RPTX News Highlights

  • RPTX's 30 day story count now stands at 6.
  • Over the past 18 days, the trend for RPTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about RPTX are ATR, CCXI and RENN.

Latest RPTX News From Around the Web

Below are the latest news stories about Repare Therapeutics Inc that investors may wish to consider to help them evaluate RPTX as an investment opportunity.

Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference

CAMBRIDGE, Mass. & MONTREAL, Quebec, October 18, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 2nd Annual Precision Oncology Conference on Wednesday, October 20, 2021 at 12:30 p.m. Eastern Time.

Yahoo | October 18, 2021

Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting

Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid tumors with specific synthetic-lethal genomic alterations. Data were presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. In the study, the data cutoff on August 15 included 101 patients. While RP-3500 looked safe and well-tolerated, the most common treatment-emergent adverse events

Yahoo | October 11, 2021

Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. & MONTREAL, October 08, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the presentation of preliminary Phase 1 monotherapy clinical data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific syn

Yahoo | October 8, 2021

28 Stocks Moving In Friday's Mid-Day Session

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis). Renren Inc. (NYSE: RENN) jumped 40.9% to $23.40. Renren, last month, named Chris Palmer as its Chief Financial Officer. ReShape Lifesciences Inc. (NASDAQ: RSLS) shares climbed 28.2% to $3.18. Maxim Group initiated coverage on Reshap

Yahoo | October 8, 2021

Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference

CAMBRIDGE, Mass. & MONTREAL, October 07, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics ("ANE Conference") concerning an upcoming oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of R

Yahoo | October 7, 2021

Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass. & MONTREAL, Quebec, September 30, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has been selected for an oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500 and a poster presentation of preclinical data for RP-3500 at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeuti

Yahoo | September 30, 2021

Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman

CAMBRIDGE, Mass. & MONTREAL, September 07, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman. He replaces Jerel Davis, Ph.D., Managing Director at Versant Ventures, who will remain a member of the Company’s Board.

Yahoo | September 7, 2021

Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL, September 02, 2021--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time.

Yahoo | September 2, 2021

Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021. We are pleased to have dosed the first patient in our Phase 1b/2 ATTACC trial of our ATR inhibitor RP-3500 and additional new PARP inhibitor c

Business Wire | August 12, 2021

What Type Of Shareholders Own The Most Number of Repare Therapeutics Inc. (NASDAQ:RPTX) Shares?

The big shareholder groups in Repare Therapeutics Inc. ( NASDAQ:RPTX ) have power over the company. Large companies...

Yahoo | August 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.7829 seconds.